Text full multimedia monochrome

First time here?

Find out more about how The Lecture List works.

Do you organise talks?

Register to tell us about them. The Lecture List is a great place to be listed, but it's also an easy place to upload your information to. It's very simple and costs nothing. Find out more

Help!

Find out what you can do to keep The Lecture List online

Why havenít we cured cancer yet? IET EngTalks: Future Science

ree to attend evening event. EngTalk speaker Prof Eleanor Stride, Oxford University will assess the challenges faced when trying to answer the question – “why haven't we cured cancer yet?"


Despite a century of incredible breakthroughs, cancer patient survival rates are still quoted in terms of 3 or 5 years and the impact of new treatments is so varied.

Could we design, manufacture and deliver ‘stimuli-responsive’ particles directly to the target site?

Oxford University’s Professor Eleanor Stride believes we can. In this year’s first Future Science EngTalk, she’ll introduce her work with ‘microbubbles’, the challenges of new drug delivery strategies and their potential for improving treatment of major diseases such as cancer or stroke.

First up, introducing Eleanor, will be our 10-minute insight speaker, Dr Jack Kreindler.

Founder of The Centre for Health and Human Performance, this is a man who wants to bring Artificial Intelligence into medical practice.


Speaker(s):

Professor Eleanor Stride | talks | www
Dr Jack Kreindler | talks | www

 

Date and Time:

4 May 2017 at 6:00 pm

Duration:

2 hours

 

Venue:

IET London: Savoy Place
2 Savoy Place
London
WC2R 0BL


Show map

Organised by:

The Instutition of Engineering & Technology
See other talks organised by The Instutition of Engineering & Technology...

 

Tickets:

Free

Available from:

http://events.theiet.org/kelvin/register.cfm

Register to tell a friend about this lecture.

Comments

If you would like to comment about this lecture, please register here.



 

Any ad revenue is entirely reinvested into the Lecture List's operating fund